Trial Condition(s):

N/A

BAY73-4506, Phase I dose-escalation intermittent dosing

Bayer Identifier:

11650

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2005-001198-81

Study Completed

Trial Purpose

To define the safety profile, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose of regorafenib administered orally as a single agent in subjects with advanced malignancies

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
76
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Freiburg, Germany, 79106

Status
Completed
 
Locations

Investigative Site

Essen, Germany, 45147

Status
Completed
 
Locations

Investigative Site

Herne, Germany, 44625

Status
Completed
 

Trial Design